Botulinum toxin treatment of epilepsia partialis continua.
Kang
Jun-Suk
JS
Krakow
Karsten
K
Roggendorf
Julia
J
Steinmetz
Helmuth
H
Hilker
Ruediger
R
D000927:Anticonvulsants / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D017036:Epilepsia Partialis Continua / Q000188:drug therapy* / Q000209:etiology; D005632:Fructose / Q000031:analogs & derivatives / Q000627:therapeutic use; D005909:Glioblastoma / Q000150:complications / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000601:surgery; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000209:etiology; D000069583:Pregabalin; D011877:Radionuclide Imaging; D015173:Supratentorial Neoplasms / Q000150:complications / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000601:surgery; D000077236:Topiramate; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use
D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D019274:Botulinum Toxins, Type A